Financing channel feed – Endpoints News

Financing channel feed

The forecast for biotech IPOs in 2017? Not nearly as hot as the industry would like

9 years ago

Eli Lilly, Novartis back a $26M round for Cavion’s work on neurological diseases

9 years ago

Neon Therapeutics bags a $70M round for early-stage neoantigen research

9 years ago

Digitalis makes its debut with $100M fund and a yen for ‘deeply technical people’

9 years ago

Biotech backer Versant arms itself with record $400M fund, targets a new wave of upstarts

9 years ago

Chinese VC syndicates wager $172M on Ascentage and Ascletis, flagging a new trend

9 years ago

Jounce rings out the old year with a $75M IPO bid for the New Year

9 years ago

Celgene, Versant back a biotech merger, building an antibody pipeline and lining up for the clinic

9 years ago

TiGenix’s second stab at an IPO bags $36M for late-stage stem cell plans

9 years ago

Flagship takes on a pioneering new fund — and name — adding $285M to advance its startup mission

9 years ago

New York gambles $1.15B in new funds and incentives in search of a biotech jackpot

9 years ago

Section 32: Ex-Google venture chief Maris pursues indie role with $230M biotech fund

9 years ago

Biogen vet Adam Koppel is raising cash for a new life sciences fund at Bain Capital

9 years ago

GSK vet Jason Gardner takes the helm of Magenta, emerging from stealth with a $48.5M round

9 years ago

Syncona, CRUK and BACIT join forces to create a $1.2B biotech investment powerhouse

9 years ago

Influential Third Rock Ventures marks a decade of high-profile wins and losses with record $616M Fund IV

9 years ago

Turning pharma castoffs into an instant fortune, Vivek Ramaswamy’s Myovant bags a $218M IPO

9 years ago

Gene editing loses its sizzle. CRISPR Therapeutics IPO debuts beneath the range

9 years ago

Nancy Stagliano bags another $45M for True North’s rare disease R&D

9 years ago

Armed antibody player ADC lands a $105M mega-round to back pipeline construction

9 years ago

Sofinnova bags $650M for a dedicated biotech fund

9 years ago

Biotechs grabbed $1.83B in VC cash in Q3. Still fast but a little less furious

9 years ago

AzurRx clips its IPO price, but manages to get the job done

9 years ago

Helsinn sets up a boutique investment fund with a roving eye for oncology upstarts

9 years ago

First page Previous page 142 143 144145146 Next page Last page